Novartis hopes to commercialise "smart lens" within 5 years

ZURICH Tue Jul 15, 2014 2:53pm IST

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013. REUTERS/Arnd Wiegmann/Files

The logo of Swiss drugmaker Novartis is seen at its headquarters in Basel October 22, 2013.

Credit: Reuters/Arnd Wiegmann/Files

Related Topics

Stocks

   

ZURICH (Reuters) - Novartis (NOVN.VX) expects the "smart lens" technology it has licensed from Google (GOOGL.O) will take several years to develop, but hopes to have a product ready for market in about five years, the drugmaker's chief executive said on Tuesday.

"This isn't going to happen overnight because it's a breakthrough technology. It's not months, we're probably talking about years. We would hope to be able to commercialise within about five years," Joe Jimenez told Reuters in an interview.

Novartis said earlier on Tuesday it had struck an agreement with Google (GOOGL.O) to develop "smart lens" technology for medical use in the eye.

(Reporting by Caroline Copley and Paul Arnold.)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Alibaba IPO

Reuters Showcase

Slow Rollout

Slow Rollout

Los Angeles iPad rollout for schools slowed by technical challenges - report.  Full Article 

CEO Watch

CEO Watch

When music stops for Oracle CEO dance, Catz may grab Ellison's chair - analysts.  Full Article 

New iPhones

New iPhones

Apple faithful line up for latest, larger iPhones  Full Article 

Cutting Jobs

Cutting Jobs

Microsoft lays off 2,100 as part of earlier job cut plan.  Full Article 

Protecting Internet

Protecting Internet

Russia eyes measures to fend off Western Internet threat - Kremlin  Full Article 

Deal Talk

Deal Talk

SAP agrees to buy expense software maker Concur for $7.3 bln  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage